SHP 465

Drug Profile

SHP 465

Alternative Names: Amphetamine salts (mixed, long acting) - Shire; d,l-Amphetamine and d-amphetamine salts (long acting) - Shire; d,l-Amphetamine and dextroamphetamine salts (long acting) - Shire; d-Amphetamine and d,l-amphetamine salts (long acting) - Shire; Dextroamphetamine and d,l-amphetamine salts (long acting) - Shire; Mydayis; SHP-465; SLI 381; SPD 465; Triple-bead mixed amphetamine salts - Shire

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 07 Jun 2018 Shire completes a phase I trial in Attention-deficit hyperactivity disorder (In children, In adolescents) in USA (PO) (NCT03325881)
  • 16 Mar 2018 Phase-I clinical trials in Attention-deficit hyperactivity disorder (In children) in USA (PO) (NCT03327402)
  • 20 Nov 2017 Shire initiates enrolment in a phase-III trial for Attention-deficit hyperactivity disorder (In children, In adolescents) in USA (PO) (NCT03325894)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top